| Domain | LVNC8-specific finding | Broader LVNC context | Key identifiers / evidence |
|---|---|---|---|
| Identity | Left Ventricular Noncompaction 8 (LVNC8) is the PRDM16-associated monogenic LVNC subtype; disease-level evidence is aggregated from published case series/reviews rather than EHR-derived individual databases. | Broad LVNC / left ventricular noncompaction is recognized as a phenotype/cardiomyopathy spectrum with controversy over whether it is a distinct cardiomyopathy or a morphologic trait shared across disorders. | Broad LVNC MONDO:0018901; PRDM16-associated disease-target evidence in Open Targets (pqac-00000000, pqac-00000003) |
| Causal gene | **PRDM16** (PR/SET domain 16) is the established causal gene for LVNC8; truncating variants are the main LVNC-associated class. | Other LVNC genes exist, but they define other subtypes or broader nonspecific LVNC phenotypes. | PRDM16 / ENSG00000142611; original human causal paper cited via review as Arndt et al. 2013, PMID 23768516 (pqac-00000003) |
| Inheritance | Predominantly **autosomal dominant** with de novo and familial cases reported; penetrance appears incomplete/variable but subtype-specific estimates are not established. | Familial screening is recommended in LVNC more generally when cardiomyopathy is suspected. | Multiple inherited and de novo truncating variants summarized in 2023 review (pqac-00000002) |
| Strongest human genetic statistic | In a cohort enrichment analysis, PRDM16 variants were found in **1.35% (6/444)** of LVNC cases versus **0.006% (7/120,147)** in gnomAD, **p = 4.0E-12**. | Supports pathogenic enrichment beyond background variation and strengthens subtype validity. | Walsh 2023, DOI: 10.1007/s12265-023-10459-6 (pqac-00000002) |
| Core phenotype | LVNC8 presents with excessive LV trabeculation/noncompaction, ventricular dysfunction, and can include dilation, heart failure, conduction disease, arrhythmia, or sudden death; severity ranges from fetal/childhood onset to adult disease. | Broader LVNC may occur isolated or alongside DCM/HCM/RCM/ARVC phenotypes and congenital heart disease. | Human variant summaries across countries/populations (pqac-00000002) |
| Imaging criteria | No PRDM16-specific imaging criteria exist; LVNC8 uses standard LVNC imaging thresholds. | Echo criterion commonly cited: end-systolic noncompacted/compacted ratio **>2.0**; CMR criterion commonly cited: ratio **>2.3**; diagnostic overcall is a known concern. | Arbustini 2014 JACC DOI: 10.1016/j.jacc.2014.08.030 (pqac-00000009); Walsh 2023 (pqac-00000010) |
| Major complications | Reported LVNC8 complications include severe biventricular heart failure, ventricular enlargement, conduction abnormalities, arrhythmias, and sudden cardiac death. | In symptomatic broader LVNC cohorts, ventricular tachyarrhythmias up to **47%** and sudden cardiac death **13–18%** have been reported; thromboembolism risk motivates anticoagulation consideration in selected patients. | PRDM16-specific case summaries (pqac-00000002); broader LVNC management review (pqac-00000008, pqac-00000007) |
| Key mechanism | PRDM16 is a compact-myocardium-enriched transcription factor required to maintain **left-ventricular compact cardiomyocyte identity**; loss causes shift toward trabecular, neuronal-like, atrial, and conduction-system programs, with downstream dysfunction. | LVNC pathogenesis broadly implicates disturbed trabeculation/compaction, developmental signaling, and myocardial maturation failure. | Wu 2022 Circulation DOI: 10.1161/CIRCULATIONAHA.121.056666 (pqac-00000005, pqac-00000004); Van Wauwe 2024 DOI: 10.26508/lsa.202402719 (pqac-00000006) |
| Latest 2023–2024 developments | 2023 multi-omics mouse work showed early **metabolic dysregulation**, oxidative stress, sex-specific substrate-use defects, and novel regulators **Pyroxd2/Pbxip1** in PRDM16-associated cardiomyopathy; 2024 single-cell RNA+ATAC work showed PRDM16 suppresses alternative atrial/conduction fates and prevents distal ventricular conduction system hyperplasia. | 2024 cardiomyopathy guidance/commentary continues to frame LV trabeculation as dynamic and emphasizes genetics plus deep phenotyping for interpretation. | Kühnisch 2023 DOI: 10.1093/cvr/cvad154 (pqac-00000012, pqac-00000014, pqac-00000017); Van Wauwe 2024 (pqac-00000006); ESC commentary 2024 DOI: 10.1093/eurheartjsupp/suae002 (context from search, not directly cited here) |
| Management | No PRDM16-targeted therapy exists; management is **phenotype-directed**: standard heart-failure therapy, arrhythmia surveillance, ICD when indicated by conventional risk factors, anticoagulation in selected patients, and family/genetic screening. | Asymptomatic patients with normal LV size/function are generally monitored; symptomatic patients are treated per HF/arrhythmia guidelines; family echocardiographic screening is recommended in familial disease. | Arbustini 2014 (pqac-00000008, pqac-00000007) |
| Trials / real-world studies | No PRDM16-specific interventional trial was identified. | Active LVNC observational studies include **NCT06024759** (risk registry, recruiting, n=500), **NCT04265040** (TORCH-Plus registry, recruiting, n=2040), **NCT06607471** (multicenter registry, recruiting), plus prior imaging/risk studies **NCT01470014**, **NCT03572569**, **NCT02568072**. | ClinicalTrials.gov records (pqac-00000024, pqac-00000021, pqac-00000025, pqac-00000023, pqac-00000022, pqac-00000020) |
| Major evidence gaps | Exact LVNC8 OMIM/MONDO subtype identifier, prevalence/incidence, penetrance, carrier frequency, genotype-specific prognosis, pregnancy/exercise guidance, and prospective treatment-response data are not well established. Most evidence is from small families, case series, reviews, and model systems. | Broader LVNC itself remains diagnostically controversial because hypertrabeculation can be physiologic (e.g., athletes, pregnancy) and may not correlate with prognosis in isolation. | Evidence-gap summary supported by genetics review and broader LVNC controversy literature (pqac-00000002, pqac-00000010) |


*Table: This compact table summarizes subtype-specific facts for PRDM16-associated Left Ventricular Noncompaction 8 and separates them from broader LVNC evidence. It highlights what is established, what is extrapolated from general LVNC literature, and where important evidence gaps remain.*